Voyager Therapeutics
Biotechnology company developing neurogenetic medicines focused on CNS delivery. The organization develops engineered viral capsids and receptor-targeting delivery modalities to enable intravenous delivery of gene therapies and non-viral therapeutics across the blood–brain barrier, advances antibody and RNA-based programs directed at neurodegenerative diseases, and supports IND-enabling and early clinical studies.
Industries
Nr. of Employees
medium (51-250)
Voyager Therapeutics
Lexington, Massachusetts, United States
Patents
Products
VY7523 (anti-tau antibody)
Monoclonal antibody program targeting tau for Alzheimer’s disease under clinical development (early-phase studies described).
VY1706 (tau-silencing gene therapy, siRNA)
A siRNA-based gene therapy program designed to lower tau for Alzheimer’s disease, developed for intravenous delivery using BBB-penetrant capsids and supported by GLP toxicology studies.
ALPL-targeted receptor-mediated CNS shuttle (neuroshuttle)
A receptor-binding non-viral shuttle approach to transport diverse therapeutic modalities across the blood–brain barrier; ALPL is described as a first validated receptor target.
VY7523 (anti-tau antibody)
Monoclonal antibody program targeting tau for Alzheimer’s disease under clinical development (early-phase studies described).
VY1706 (tau-silencing gene therapy, siRNA)
A siRNA-based gene therapy program designed to lower tau for Alzheimer’s disease, developed for intravenous delivery using BBB-penetrant capsids and supported by GLP toxicology studies.
ALPL-targeted receptor-mediated CNS shuttle (neuroshuttle)
A receptor-binding non-viral shuttle approach to transport diverse therapeutic modalities across the blood–brain barrier; ALPL is described as a first validated receptor target.
Services
Licensing of engineered capsids and collaborations to combine delivery capsids or receptor technologies with external payloads; includes deal structures with upfront payments, milestones, and royalties.
Internal development of IND-enabling programs including GLP toxicology, pharmacology, and manufacturing process development to support regulatory submissions.
Licensing of engineered capsids and collaborations to combine delivery capsids or receptor technologies with external payloads; includes deal structures with upfront payments, milestones, and royalties.
Internal development of IND-enabling programs including GLP toxicology, pharmacology, and manufacturing process development to support regulatory submissions.
Expertise Areas
- AAV capsid engineering
- Neurogenetic medicine development
- Blood–brain barrier delivery strategies
- Non-viral receptor-mediated CNS delivery
Key Technologies
- AAV capsid engineering
- RNA-based capsid screening (RNA-driven biopanning)
- Directed evolution
- Receptor-mediated transcytosis targeting (e.g., ALPL receptor)
News & Updates
Press release announcing CEO succession and appointment of President.
Quarterly financial and operational results report.
Conference poster describing GLP non-human primate toxicology and pharmacology supporting an IV-delivered BBB-penetrant AAV tau-targeting program.
Peer-reviewed methods paper describing RNA-driven biopanning for rapid evolution of BBB-penetrant AAV capsids.
Press release announcing CEO succession and appointment of President.
Quarterly financial and operational results report.
Conference poster describing GLP non-human primate toxicology and pharmacology supporting an IV-delivered BBB-penetrant AAV tau-targeting program.
Peer-reviewed methods paper describing RNA-driven biopanning for rapid evolution of BBB-penetrant AAV capsids.